John McCafferty
CTO Maxion Therapeutics
Seminars
Thursday 3rd December 2026
KnotBody Technology®: Integrating Peptide Sequences into Antibody Therapeutics
9:00 am
- KnotBody technology: An overview of Maxion Therapeutics’ approach to engineering knottin-derived peptide sequences within an antibody framework
- The Kv1.3 example: How the platform is applied to engineer peptide sequences targeting the Kv1.3 ion channel, a target of interest in autoimmune and inflammatory disease
- Designing next-generation biologics: The rationale for combining peptide-based target recognition with an antibody context, and the potential of this approach to expand therapeutic possibilities.
